210 related articles for article (PubMed ID: 11695564)
21. Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice.
Muto S; Katsuki M; Horie S
Cancer Sci; 2007 Oct; 98(10):1549-56. PubMed ID: 17683512
[TBL] [Abstract][Full Text] [Related]
22. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
23. Mutation and overexpression of the transgene in ethylnitrosourea-induced tumors in mice carrying a human prototype c-Ha-ras gene.
Toyosawa K; Tanaka K; Imai T; Yasuhara K; Koujitani T; Hirose M; Mitsumori K
Toxicol Pathol; 2003; 31(5):491-5. PubMed ID: 14692617
[TBL] [Abstract][Full Text] [Related]
24. Carcinogenic susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 mice.
Okamura M; Moto M; Kashida Y; Machida N; Mitsumori K
Toxicol Pathol; 2004; 32(4):474-81. PubMed ID: 15223773
[TBL] [Abstract][Full Text] [Related]
25. Lack of modifying effects of eugenol on development of lung proliferative lesions induced by urethane in transgenic mice carrying the human prototype c-Ha-ras gene.
Koujitani T; Yasuhara K; Tamura T; Onodera H; Takagi H; Takizawa T; Hirose M; Hayashi Y; Mitsumori K
J Toxicol Sci; 2001 Aug; 26(3):129-39. PubMed ID: 11552296
[TBL] [Abstract][Full Text] [Related]
26. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
27. Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains.
Ozaki M; Ozaki K; Watanabe T; Uwagawa S; Okuno Y; Shirai T
Toxicol Pathol; 2005; 33(2):267-71. PubMed ID: 15902970
[TBL] [Abstract][Full Text] [Related]
28. Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of the human c-Ha-ras transgene.
Ogawa K; Imaida K; Masui T; Kawabe M; Hasegawa R; Kato K; Ito N; Shirai T
Carcinogenesis; 1996 Feb; 17(2):341-5. PubMed ID: 8625461
[TBL] [Abstract][Full Text] [Related]
29. Possible mechanism on enhanced carcinogenesis of genotoxic carcinogens and unsolved mechanisms on lesser carcinogenic susceptibility to some carcinogens in rasH2 mice.
Mitsumori K
J Toxicol Sci; 2003 Dec; 28(5):371-83. PubMed ID: 14746341
[TBL] [Abstract][Full Text] [Related]
30. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
31. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
32. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
33. Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl-N-nitrosourea.
Watanabe T; Kashida Y; Yasuhara K; Koujitani T; Hirose M; Mitsumori K
Cancer Lett; 2002 Dec; 188(1-2):39-46. PubMed ID: 12406546
[TBL] [Abstract][Full Text] [Related]
34. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
35. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations in HCA-induced tumors.
Ushijima T; Makino H; Kakiuchi H; Inoue R; Sugimura T; Nagao M
Princess Takamatsu Symp; 1995; 23():281-91. PubMed ID: 8844820
[TBL] [Abstract][Full Text] [Related]
37. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Cho WS; Jeong J; Choi M; Park SN; Han BS; Son WC
Arch Toxicol; 2011 Jan; 85(1):59-66. PubMed ID: 20358181
[TBL] [Abstract][Full Text] [Related]
38. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice.
Okamura M; Unami A; Moto M; Muguruma M; Ito T; Jin M; Oishi Y; Kashida Y; Mitsumori K
Cancer Lett; 2007 Jan; 245(1-2):321-30. PubMed ID: 16530936
[TBL] [Abstract][Full Text] [Related]
39. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW
Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158
[TBL] [Abstract][Full Text] [Related]
40. Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.
Urano K; Tamaoki N; Nomura T
Vet Pathol; 2012 Jan; 49(1):16-23. PubMed ID: 22146850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
